Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Travera Inc
Seagen Inc.
KaliVir Immunotherapeutics
iOnctura
Sotio Biotech Inc.
Endeavor Biomedicines, Inc.
Novartis
Kezar Life Sciences, Inc.
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
Incyte Corporation
Actym Therapeutics, Inc.
Incyte Corporation
Incyte Corporation
Turnstone Biologics, Corp.
Taproot Health
Molecular Templates, Inc.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Pfizer
NGM Biopharmaceuticals, Inc
Rain Oncology Inc
Xencor, Inc.
Incyte Corporation
AbbVie
AbbVie
Infinity Pharmaceuticals, Inc.
Novartis
MacroGenics
Incyte Corporation
Incyte Corporation
Incyte Corporation
Shenzhen BinDeBio Ltd.
Novartis
Mannkind Corporation